Vaccination of cancer patients for preventing cancer development

Phase 1

• Conditions: ymphoma.; B-cell lymphoma, unspecified

• Registration Number: IRCT138712071715N1
• Lead Sponsor: Mazandaran University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

Presence of diffuse b cell lymphoma
Exclusion criteria: Presence o any other kind of cancer except for lymphoma

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The number of TCD4. Timepoint: one week after injection. Method of measurement: Flocytometry.;The number of TCD8. Timepoint: one week after injection. Method of measurement: Flocytometry.

Secondary Outcome Measures

Name	Time	Method
Interleukin 2. Timepoint: 7 to 14 days after injection. Method of measurement: eliza.;Interleukin 4. Timepoint: 7 to 14 days after injection. Method of measurement: ELIZA method.;Interleukin 10. Timepoint: 7 to 14 days after injection. Method of measurement: ELIZA method.;Interleukin 17. Timepoint: 7 to 14 days after injection. Method of measurement: ELIZA method.